Literature DB >> 21856477

Injectable extended-release naltrexone for opioid dependence.

Evgeny Krupitsky, Edward V Nunes, Walter Ling, Ari Illeperuma, David R Gastfriend, Bernard L Silverman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21856477     DOI： 10.1016/S0140-6736(11)61331-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Naltrexone: A Pan-Addiction Treatment?

Authors:  Elias Aboujaoude; Wael O Salame
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

2.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

3.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

Review 4.  Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.

Authors:  Tae Woo Park; Peter D Friedmann
Journal:  R I Med J (2013)       Date:  2014-10-01

5.  Chronic Pain, Opioid Use Disorder, and Clinical Management Among Older Adults.

Authors:  Sudheer Potru; Yi-Lang Tang
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-07-09

6.  Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Authors:  Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

7.  Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.

Authors:  Rachel M Burns; Rosalie L Pacula; Sebastian Bauhoff; Adam J Gordon; Hollie Hendrikson; Douglas L Leslie; Bradley D Stein
Journal:  Subst Abus       Date:  2015-11-13       Impact factor: 3.716

8.  A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Martha J Bojko; Alyona Mazhnaya; Iuliia Makarenko; Sergii Filippovych; Sergii Dvoriak; Frederick L Altice; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2018-01-05

9.  Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.

Authors:  Albert Stuart Reece
Journal:  Subst Abuse       Date:  2012-09-27

Review 10.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.